Stallergenes group

Governance

-  Print

 

 

Albert Saporta, Chairman

Roberto Gradnik, Chief Executive Officer

 

 

Stallergenes propels immunotherapy into modernity

"Dealing effectively and sustainably with severe respiratory allergies and improving the quality of life of our patients have been our commitments for the past 50 years.

This anniversary offers Stallergenes the opportunity to measure the path we have already taken, filled with great accomplishments in allergen immunotherapy for the benefit of patients, and looking forward to a future of continued innovation.

A long-time partner of allergy specialists, Stallergenes' main purpose is to use its strong expertise to help patients suffering from severe allergic rhinitis, responding to a high therapeutic need.

Innovation, at the heart of Stallergenes’ identity, is furthering the recognition of allergen immunotherapy treatments as pharmaceutical specialties gained from an improved level of evidence.

Today we have ambitious goals, aimed at making Stallergenes an international biopharmaceutical company, leader in its field."

Dr. Roberto Gradnik, Chief executive officer

Mission and Vision

Mission:

To provide allergy specialists with registered allergen pharmaceuticals to treat patients suffering from allergic respiratory diseases, not adequately controlled with symptomatic treatments

 

Vision:


Be the worldwide innovation-driven biopharmaceutical leader for allergen immunotherapy
٠Drawing on our expertise in the field of allergens,
٠Providing registered treatments, based on acknowledged evidence-based medicine,
٠Firmly anchoring allergen vaccines as part of the management of allergic respiratory disease,
٠Fostering better compliance, so as to enhance patient satisfaction,
٠Committed to supporting the practice of allergology with an unmatched service offer.